Galderma Laboratories LP v. Tolmar Inc.
1:10-cv-00045
Overview
Parties
Defendant
Actavis Mid Atlantic LLC Operating Company
Represented By
7 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Tolmar Inc. Operating Company
Represented By
11 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Plaintiff
Galderma Research and Development SNC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Galderma SA NPE (Individual / Inventor)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Galderma Laboratories LP NPE (Individual / Inventor)
Represented By
4 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 21 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7579377
Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
|
Filed: 2004-09-10
Issued: 2009-08-25
|
Expired (Term Ended)
+730d PTA
Expires: 2026-09-10
|
|
|
US7737181
Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
|
Filed: 2006-07-28
Issued: 2010-06-15
|
Expired (Term Ended)
Expires: 2024-08-29
|
|
|
US7834060
Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
|
Filed: 2009-05-07
Issued: 2010-11-16
|
Expired (Term Ended)
Expires: 2023-05-16
|
|
|
US7838558
Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
|
Filed: 2008-04-15
Issued: 2010-11-23
|
Active (1.4 yrs remaining)
Expires: 2028-04-15
|
|
|
US7868044
Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
|
Filed: 2010-05-03
Issued: 2011-01-11
|
Active (3.4 yrs remaining)
Expires: 2030-05-03
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.
High PTA (+730 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
1
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings